The effects of psychotropic drugs on the cardiovascular system.
Clinicians may encounter substantial numbers of patients with cardiovascular disease who may be receiving cardiovascular medications and who also need psychopharmacologic intervention. To provide information regarding the management of such patients, the pharmacology of the major classes of psychoactive agents is reviewed with respect to their cardiotoxicity, cardiovascular side effects, and drug-drug interactions. Management of the cardiovascular complications of psychotropic overdose is discussed, and potential therapeutic uses of psychoactive medications in patients with cardiovascular pathology are noted.
D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002319:Cardiovascular System / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D009200:Myocardial Contraction / Q000187:drug effects; D011619:Psychotropic Drugs / Q000009:adverse effects*
D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D002317:Cardiovascular Agents; D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D011619:Psychotropic Drugs